|
業務類別
|
Biotechnology |
|
業務概覽
|
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways. |
| 公司地址
| 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902 |
| 電話號碼
| +1 848 230-7430 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.adlainortye.com |
| 員工數量
| 109 |
| Mr. Yang Lu |
Chief Executive Officer and Chairman of the Board |
-- |
10/04/2026 |
| Dr. Xiaofeng Alex Ye, PhD |
Chief Financial Officer |
-- |
10/04/2026 |
| Dr. Archie Tse |
President and Head of Research and Development |
-- |
10/04/2026 |
|
|
| Mr. Yang Lu |
Chief Executive Officer and Chairman of the Board |
10/04/2026 |
| Mr. Ming Lun Alan Tse |
Independent Director |
10/04/2026 |
| Mr. Shaorong Liu |
Independent Director |
10/04/2026 |
| Dr. Lars Erik Birgerson |
Director |
10/04/2026 |
| Mr. Baozhong Wei |
Independent Director |
10/04/2026 |
| Dr. Ping Ji |
Director |
10/04/2026 |
| Dr. Roger Sawhney, M.D. |
Independent Director |
10/04/2026 |
|
|
|
|
